Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 5.6% – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price dropped 5.6% on Friday. The stock traded as low as $36.00 and last traded at $36.00. 200 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 2,603 shares. The stock had previously closed at $38.12.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company’s 50-day simple moving average is $46.05 and its 200 day simple moving average is $46.28. The company has a market cap of $2.58 billion, a PE ratio of 5.97 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.